Sunday July 3
18.30 – 21.00
Registration
Welcome Reception with “Apericena”
(Presidio Mattioli, Via Mattioli 10)
Monday July 4
MORNING SESSION
8.30-9.00 Welcome remarks: Lorenzo Leoncini and Pankaj Trivedi
09.00-11.00 EBV infection and viral replication
Chair: Michelle West and Paul Farrell
9.00 Topic Lecture
Erle Robertson, Department of Otorhinolaryngology-Head and Neck Surgery, and the Tumor Virology Program, University of Pennsylvania, USA
M6A modification of the host epitranscriptome attenuates IFN signaling and Promotes EBV lytic reactivation
09.20 Michael T. McIntosh (USA). EBV LMP-1 forms a K+ selective oncochannel that supports LYTIC virus release
09.35 Francesco Baccianti (Germany). Epstein-Barr virus infection of resting B cells requires activation of multiple signaling pathways that converge onto the stress protein ZFP36L1
9.50 Sumita Bhaduri-McIntosh (USA). EA-d directs traffic at the intersection of EBV transcription and replication
10.05 Ana Catalina Blazquez (Argentina). Could Epstein Barr virus type 2 asymmetric circulation be explained with an Immunoinformatic approach?
10.20 Sankar Swaminathan (USA). Effects of RAD21 and CTCF on EBV reactivation from latency
10.35 Davide Maestri (USA, Italy). Epstein-Barr Virus rewires host genome through CTCF and PARP1 relocation
11.00 – 11.20 Coffee break and Poster viewing
11.20-13.00 EBV latency program and reactivation
Chair: Pankaj Trivedi and Alberto Faggioni
11.20 Topic Lecture
Paul Liebermann, Gene Expression & Regulation Program, The Wistar Institute, USA
Control of EBV Latency by EBNA1 in Cancer and Multiple Sclerosis
11.40 Ezgi Akidil (Germany). Histone Chaperone CAF1 is essential for the survival of EBV-infected primary B cells and the establishment of viral latency
11.55 Katherine A. Willard (USA). Novel Epstein Barr virus strains isolated from endemic Burkitt lymphoma patients display unusual and reversible spontaneous lytic phenotypes
12.10 Bill Sugden (USA). Epstein-Barr virus manipulates cellular chromatin structure during its lytic phase
12.25 Jillian A. Bristol (USA). Reduced IRF4 level contributes to lytic phenotype of type 2 EBV infected B cells
12.40 Italo Tempera (USA). PARP1 and CTCF interaction guides EBV chromatin refolding to promote viral gene expression and sustain cell proliferation during latency
13.00 – 14.30 Lunch and poster viewing
AFTERNOON SESSION
14.30-16.00 Mechanism of EBV oncogenesis
Chairs: Sankar Swaminathan and Gian Maria Rossolini
14.30 Topic Lecture
Bill Sugden, WI Institutes for Medical Research, Università del Wisconsin-Madisom, USA
What Epstein-Barr virus contributes to B cell lymphoma.
14.50 Alejandro Casco (USA). What can a fluorescent Epstein-Barr virus tell us about host-shutoff?
15.05 Elliott D. SoRelle (USA). Time-resolved multiomics reveal distinct B cell fates and gene regulatory signatures in the early stages of Epstein-Barr Virus infection
15.20 Noemi Nagy (Sweden).The Epstein-Barr virus deubiquitinating enzyme BPLF1 supports cell survival and virus production by regulating the activity of topoisomerase II
15.35 Sheldon Steyn (Germany). Oncogenic properties of the Epstein Barr Virus Large Tegument Protein
15.50 Francesca Manara (France). Key epigenetic events during EBV-mediated B cell transformation
16.10 – 16.30 Coffee break and Poster Viewing
16.30-18.00 EBV Associated Epithelial Cancers
Chairs: Bill Sugden and Anita De Rossi
16.30 Topic Lecture
Hironori Yoshyama, Department of Microbiology, Shimane University, Izumo, Shimane, Japan
Epithelial cell tumors
16.50 Shannon C. Kenney (USA). LMP1 promotes proliferation, and inhibits differentiation, in EBV-infected telomerase-immortalized normal oral keratinocytes (NKs) by activating the hippo pathway effectors, YAP and TAZ
17.05 Salvatore Tornambè (Italy). EBV persistence in gastric cancer cases conventionally classified as EBER-ISH negative
17.20 Ciara Leahy (Ireland). Exploring gene and protein expression in the tumour and tumour microenvironment of nasopharyngeal carcinoma
17.35 Atsushi Kaneda (Japan). Epstein-Barr virus infection rewires host chromatin structure and epigenetically contributes to tumorigenesis in tissue wide manner
17.50 Joanna B. Wilson (UK). Mouse models of EBV associated disease, from understanding mechanism to pre-clinical model
Tuesday July 5
MORNING SESSION
09.00-11.00 EBV Associated Lymphomas- Session 1: Diffuse Large B Cell Lymphoma and Burkitt Lymphoma
Chairs: Cesarman Ethel and Stefan Dojcinov
09.00 Topic Lecture I
Ioannis Anagnostopoulos, Institut für Pathologie, Universität Würzburg, Germany
EBV- positive diffuse large B-cell lymphoma
09.20 Topic Lecture II
Rosemary Rochford, Department of Immunology and Microbiology, University of Colorado, USA
Uncovering the etiology of Burkitt lymphoma
9.40 Tamara Soledad Mangiaterra (Argentina). Detection of EBV antigens by unconventional methods in DLBCL from Argentina diagnosed as EBV negative
9.55 Rebecca L Hutcheson (USA). Sequential CRISPR knockout screening reveals cellular genes compensating for Epstein-Barr Virus in Burkitt Lymphoma cell lines
10.10 Amy Chadburn (USA). Revisiting EBV expression patterns in lymphoma
10.25 Jez L. Marston (USA). EBV latency III program induces expression of HERVK(HML2) loci in Burkitt Lymphoma cell lines
10.40 Cliff I. Oduor (USA). Patient-derived endemic Burkitt Lymphoma avatar mouse models for exploring inter-patient tumor variation and testing targeted therapies
11.00 – 11.20 Coffee break and Poster viewing
11.20-13.00 EBV Associated Lymphomas: Session 2
Chairs: Amy Chadburn and Antonino Carbone
11.20 Topic Lecture
Leticia Quintanilla Fend, Department of Pathology, University of Tubingen, Germany
Challenges in EBV+ T and NK cell lymphoproliferations
11.45 Aisling Ross (Ireland, UK). Investigating Lymphomagenesis using Transformed Germinal Centre B Cells as a Model of EBV+ Diffuse Large B cell Lymphoma
12.00 Gabriela Samayoa-Reyes (USA). Effect of age and malaria infection on Epstein – Barr viral reactivation in children
12.15 Paul J. Farrell (UK).Epstein-Barr Virus genome deletions in EBV+ T/NK cell lymphoproliferative diseases
12.30 Nader Bayda (France). Analysis of Epstein-Barr virus transcriptome in angioimmunoblastic T cell lymphoma (AITL) comparatively to other human lymphomas
12.45 Ioannis Anagnostopoulos (Germany). Epstein-Barr-Virus infectionpatterns in nodular lymphocytepredominant Hodgkin-lymphoma
13.00 – 14.30 Lunch and poster viewing
AFTERNOON SESSION
14.30-16.00 EBV and tumor microenvironment
Chairs: Ann Moormann and Falko Fend
14.30 Topic Lecture
Christian Münz, Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, Switzerland
The microenvironment of EBV specific immune control
14.50 Éanna Fennell (Ireland). Highly multiplexed, single-cell spatial phenotyping of Epstein-Barr virus associated lymphomas
15.05 Ann M. Moormann (USA). Single cell landscape of tumor infiltrating T cells in endemic Burkitt lymphoma Patients
15.20 Agustina Moyano (Argentina). Epstein Barr Virus´ role in the interplay of tonsil macrophages polarization and periphery cytokine expression
15.35 Jennifer Saliba (France). Role of fucoidans in the restoration of the anti-tumor T-cell response inhibited by EBV latency III B cells via the PD-L1 immune checkpoint
15.50 Maria Chiara Siciliano (Italy). Epstein-Barr virus orchestrate the Tumor Microenvironment of Burkitt Lymphoma
16.10 – 16.30 Coffee break and poster viewing
16.30-17.30 Henle Lecture 2022
Shannon Kenney “EBV regulation in B cells versus epithelial cells”
17.30-18.00 General assembly: EBV association members
20.30 Social Dinner
Wednesday July 6
MORNING SESSION
Chairs: Eleni Anastasiadou and Lori Frappier
09.00-11.00 EBV non-coding RNA regulation and other trasforming mechanisms
9.00 Topic Lecture
Lori Frappier, Department of Molecular Genetics, University of Toronto, Toronto, Canada
Analysis of Changes in the SUMO Proteome In Response To EBV Lytic Infection Identifies the TRIM24/28/33 Complex as an EBV Regulator
9.20 Ashley M Campbell (Canada). BGLF2 interferes with cellular miRNA function by binding RISC
9.35 Jiayan LIU (China). Role of Epstein-Barr Virus lnc-BARTs/BRD4 Axis in Promoting Nasopharyngeal Carcinoma
9.50 Suk Kyeong Lee (Korea). Epstein-Barr Virus miR-BART1-3p Regulates the miR-17-92 Cluster by Targeting E2F3
10.05 Rena R. Xian (USA). Can EBV CPG methylation in plasma distinguish EBV lymphoma (+) subtypes?
10.20 Eleni Anastasiadou (Italy). Epstein-Barr virus: from kisses to cancer, an ingenious immune evader
10.35 Eric C.Johannsen (USA). An EBV mutant deleted for the IE locus reveals Rta to be the dominant early gene activator and Zta acts primarily at OriLyt
11.00 Coffee break and poster viewing
11.20 – 13.00 EBV and Multiple Sclerosis
Chairs: Christian Münz and Jaap Middeldorp
11.20-13.00 EBV and Multiple Sclerosis
11.20 Topic Lecture
Ascherio Alberto, Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
EBV as the leading cause of multiple sclerosis
11.40 Marc S. Horwitz (Canada). Epstein-Barr virus infection promotes Th1-mediated disease in a humanized immune mouse model of multiple sclerosis
11.55 John B. Harley (USA). Proline-rich EBNA1 epitopes initiate cross-reacting autoantibodies in Systemic Lupus Erythematosus (SLE) & Multiple Sclerosis (MS)
12.10 Caterina Veroni (Italy). Detection of EBV nucleic acids in brain immune infiltrates, cerebrospinal fluid and peripheral blood of patients with multiple sclerosis
12.30 – 14.00 Poster session and Lunch
AFTERNOON SESSION
14.00-16.30 Diagnostics, Vaccines, and Therapy
Chairs: Richard Ambinder and Gianni Pozzi
14.00 Topic Lecture
Jeffery Cohen, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
Strategies to prevent EBV-associated diseases
14.20 Michelle J. West (UK). Natural variants of EBNA1 differ in their DNA binding and replication properties and sensitivity to inhibitors
14.35 Wei Bu (USA). A Potent GP42 Monoclonal Antibody Neutralizes EBV Infection and Protects Humanized Mice from EBV Infection
14.50 Silvia Giunco (Italy). Anti-proliferative effects of combined treatment with TERT inhibitor and chemotherapeutic agents in EBV-positive malignant B cells xenografted in zebrafish
15.05 Arnd Kieser (Germany). Highly Efficient small molecule inhibitors of LMP1-TRAF2 interaction block LMP1 signaling and interfere with LCL and PTLD Survival
15.20 Harman Malhi (USA). Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge
15.35 Ayman Elguindy (USA). Targeting Epstein-Barr virus-associated malignancies using “Kick and Kill”
15.50 Maher K Gandhi (Australia). The tumour microenvironment and genetic profile of EBV+ primary CNS lymphomas in amenable to combination 3rd party EBV-specific VST, Ibrutinib and Rituximab.
16.05 Vijayendra Dasari (Australia). A lymph node targeted molecular adjuvant and engineered subunit antigen vaccine promotes potent cellular and humoral immunity to Epstein-Barr virus in HLA-expressing mice
16.20 Closing remarks